Protalix BioTherapeutics
PLX
34 hedge funds and large institutions have $6.39M invested in Protalix BioTherapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
7,350% more call options, than puts
Call options by funds: $149K | Put options by funds: $2K
104% more capital inflows, than outflows
Capital inflows: $3.01M | Capital outflows: $1.47M
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
1.08% more ownership
Funds ownership: 7.18% → 8.25% (+1.1%)
0% more funds holding
Funds holding: 34 → 34 (0)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Highbridge Capital Management
New York
|
+$2.93M |
| 2 |
Two Sigma Securities
New York
|
+$30.5K |
| 3 |
Virtu Financial
New York
|
+$18.9K |
| 4 |
Goldman Sachs
New York
|
+$18.2K |
| 5 |
Guggenheim Capital
Chicago,
Illinois
|
+$2.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$414K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$319K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$276K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$191K |
| 5 |
Renaissance Technologies
New York
|
-$128K |
PLX Hedge Fund Activity: Q3 2017 in Review
34 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2017, worth a combined $6.39M — down 16% from $7.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PLX positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $2.93M. The largest seller was Oxford Asset Management, cutting an estimated $414K.
- 34 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $6.39M of Protalix BioTherapeutics stock for Q3 2017, down 16% quarter-over-quarter.
- 5 funds opened new Protalix BioTherapeutics positions in Q3 2017 and 4 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q3 2017 was Highbridge Capital Management, an estimated $2.93M added.
- The largest Protalix BioTherapeutics seller in Q3 2017 was Oxford Asset Management, an estimated $414K sold.
Based on aggregated 13F filings for Q3 2017.